ArticleRadiation oncology journal2025
Role of radiotherapy in the management of breast cancer with skin involvement.
Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Response to "Optimizing palliative radiotherapy for breast cancer with skin involvement: technical and methodologic considerations".Radiation oncology journal · 2026Article
- The Role of Electrochemotherapy in Managing Cutaneous Metastases from Breast Carcinoma: A Narrative Review.Biomedicines · 2025Review
- Optimizing palliative radiotherapy for breast cancer with skin involvement: technical and methodologic considerations.Radiation oncology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThis study aimed to evaluate the effect of radiotherapy (RT) on symptomatic relief and tumor control in patients with breast cancer with skin involvement. MATERIALS AND
methodsThis retrospective study included patients who received palliative RT of the breast or chest wall for breast cancer with skin involvement. Progression-free survival, freedom from local progression (FFLP), and symptomatic response were evaluated. The prescribed dose to tumor was calculated as the biologically effective dose (BED) using α/β of 4. Symptomatic responses were evaluated until 6 months after RT.
resultsOf the 43 patients included in this study, 48 Gy in 15 fractions was the most common regimen, and the median BED was 86.4 Gy (range, 24.0 to 120.0). With a median follow-up of 15.1 months (range, 1.6 to 63.5), the median FFLP and progression-free survival were 8.4 and 3.6 months, respectively. The 1-year FFLP rates in patients who received BED >75 Gy and BED ≤75 Gy were 78.3% and 49.7%, respectively (p = 0.046). Within 6 months after RT, 75% of patients showed relief of discharge, 67% showed relief of bleeding, and 37% showed relief of pain. There was no grade 3 or higher skin toxicity or other adverse events.
conclusionPalliative RT is a safe and effective treatment option for patients with breast cancer with skin involvement, providing symptomatic relief. The administration of BED ≥75 Gy can offer a benefit in achieving durable local control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.